Lilly Loses UK High Court Alimta Battle
This article was originally published in Scrip
Executive Summary
Eli Lilly & Co. will continue to "vigorously defend" its Alimta (pemetrexed disodium) patents in the UK, France, Italy and Spain, it said, following a UK High Court ruling last week that will allow competitor Actavis to market a generic version of the cancer drug.
You may also be interested in...
UK Court Shakes Up Test For Equivalent Infringement In Lilly/Actavis Case
The UK Supreme Court has shaken up the test for equivalent infringement in the UK, which is good news for patent owners out to catch infringers.
UK Court Shakes Up Test For Equivalent Infringement In Lilly/Actavis Case
The UK Supreme Court has shaken up the test for equivalent infringement in the UK, which is good news for patent owners out to catch infringers.
Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth
Lilly’s new CEO David Ricks said he had confidence in the Trump Administration’s ability to understand and respond to the biopharma industry’s needs as well as address drug pricing concerns. The company’s fourth quarter earnings could insulate it from cost criticism, since sales volume drove revenue gains, not prices.